English  |  中文
Please enter exact key words
Program Indication Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
CAR-T Therapy
CHR-106-CAR-T Cancer
RP215-CAR-T Cancer
PTG-01 Acute Lymphoblastic Leukemia (ALL)
Antibody Therapy
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy(DR)
hGHR106 Cancer; Reproductive Disease;
RP215 Cancer
CD3XCD20 bsAb Lymphomas
Cl3hmAb Acquired immune deficiency syndrome (AIDS)
Fusion Protein Therapy
P75NEURO Neurological Diseases

Founded in recent years, Protheragen is still a toddler, but continues to grow with the help of many scientists in the company. We value virtues and talented researchers, so we love to work with projects that came up by people with good character. By placing people at the center of each project, Protheragen pursues a flexible and unique business concept that revolves around the research needs of the researchers. Protheragen serves as an incubator for many early stage drug development programs towards commercialization. Along the way, we also help bridging investments and life-changing research innovations.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com

Opening Hours

Monday — Sunday: 9am — 6pm